Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets

Part # PS282


Zhi-jie Jey Cheng, Jamison Grailer, Pete Stecha, Jun Wang, Jim Hartnett, Frank Fan, and Mei Cong
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711 

Current methods used to measure the activity of antibody and other biologics drugs designed to target immune checkpoint receptors rely on primary human cells and measurement of functional endpoints such as cell proliferation, cell surface marker expression, and cytokine production. These assays are laborious and highly variable due to their reliance on donor primary cells, complex assay protocols, and unqualified assay reagents. As a result, these assays are difficult to establish in quality-controlled drug development settings.
To overcome these challenges, we developed a suite of cell-based bioluminescent reporter bioassays for individual and combination immune checkpoint immunotherapy targets including:
- PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT
- GITR, 4-1BB, CD40, OX40
These mechanism of action (MOA)-based bioassays are available in “thaw-and-use” format and demonstrate high specificity, sensitivity, and reproducibility.

Printed in USA.